Proactive Investors - Run By Investors For Investors

Futura Medical kicks off Phase III study on erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive's Andrew Scott they've begun a Phase III study for their MED2002 erectile dysfunction treatment, while the CSD500 erectogenic condom's received shelf life approval from regulators.

Barder says the MED2002 trial, which is expecting its first patients to enter study within the next month, will involve 1,000 patients with headline data expected by the end of 2019.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full FUM profile View Profile

Futura Medical PLC Timeline

Newswire
December 17 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use